A detailed history of Vanguard Group Inc transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,269,466 shares of VRCA stock, worth $10.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,269,466
Previous 1,268,710 0.06%
Holding current value
$10.1 Million
Previous $7.51 Million 23.22%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.89 - $9.56 $4,452 - $7,227
756 Added 0.06%
1,269,466 $9.25 Million
Q1 2024

May 10, 2024

BUY
$4.74 - $6.81 $36,066 - $51,817
7,609 Added 0.6%
1,268,710 $7.51 Million
Q4 2023

Feb 14, 2024

BUY
$2.93 - $7.32 $100,331 - $250,658
34,243 Added 2.79%
1,261,101 $9.23 Million
Q3 2023

Nov 14, 2023

BUY
$3.75 - $7.46 $9,063 - $18,030
2,417 Added 0.2%
1,226,858 $4.76 Million
Q2 2023

Aug 14, 2023

BUY
$5.32 - $6.79 $567,452 - $724,248
106,664 Added 9.54%
1,224,441 $7.07 Million
Q1 2023

May 15, 2023

BUY
$2.88 - $8.51 $273,568 - $808,356
94,989 Added 9.29%
1,117,777 $7.27 Million
Q4 2022

Feb 10, 2023

BUY
$2.09 - $3.39 $21,301 - $34,550
10,192 Added 1.01%
1,022,788 $2.81 Million
Q2 2022

Aug 12, 2022

BUY
$1.81 - $8.93 $579,990 - $2.86 Million
320,437 Added 46.3%
1,012,596 $1.95 Million
Q1 2022

May 13, 2022

SELL
$7.59 - $9.49 $273 - $341
-36 Reduced 0.01%
692,159 $5.61 Million
Q4 2021

Feb 14, 2022

BUY
$9.1 - $13.36 $172 - $253
19 Added 0.0%
692,195 $6.34 Million
Q3 2021

Nov 12, 2021

BUY
$9.55 - $13.96 $41,685 - $60,935
4,365 Added 0.63%
692,176 $8.65 Million
Q2 2021

Aug 13, 2021

BUY
$9.77 - $15.33 $6.72 Million - $10.5 Million
687,811 New
687,811 $7.77 Million

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.